Related Experiment Video
Updated: Apr 30, 2026
11:08
Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
1.9K
A killer choice for cancer immunotherapy.
Tobi L Schmidt1, Robert S Negrin, Christopher H Contag
1Molecular Imaging Program at Stanford (MIPS), Department of Pediatrics, Stanford Center for Photomedicine, Stanford University School of Medicine, Clark Center, East Wing E150, 318 Campus Drive, Stanford, CA, 94305-5439, USA.
Immunologic Research
|May 6, 2014
Summary
Next-generation cytokine-induced killer (CIK) cell therapies show promise for cancer treatment. These cell-based immunotherapies can overcome tumor barriers and enhance efficacy for durable responses.
Area of Science:
- Immunology
- Oncology
- Cell Therapy
Background:
- Cell-based immunotherapies offer synergistic potential with conventional cancer treatments.
- Current limitations include tissue barrier penetration, antigen tolerance, and tumor immunosuppression.
- Understanding immune cell signaling and trafficking is key to overcoming these obstacles.
Purpose of the Study:
- To discuss next-generation cytokine-induced killer (CIK) cell therapies.
- To highlight CIK cell applications for treating diverse cancers.
- To explore strategies for overcoming challenges in cell-based immunotherapy.
Main Methods:
- Selection of immune cell populations for adoptive transfer.
- Development of delivery strategies to circumvent biological barriers.
- Leveraging knowledge of immune cell signaling and trafficking.
Main Results:
- Cytokine-induced killer (CIK) cells exhibit promising trafficking patterns.
- CIK cells demonstrate effective delivery of synergistic therapeutics.
- CIK cells show potential for stand-alone anti-tumor efficacy.
Conclusions:
- Next-generation CIK therapies represent a promising approach for cancer treatment.
- CIK cells can be engineered to overcome tumor microenvironment challenges.
- Further development of CIK therapies may lead to durable anti-cancer responses and prevent recurrence.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
01:30Cancer Vaccines
1.3K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
02:57Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K
02:49Cancer Therapies
8.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.5K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:56Treatment Resistant Cancers
2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K